FY2025 Earnings Forecast for WVE Issued By Cantor Fitzgerald

Key Points

• Cantor Fitzgerald revised its FY2025 earnings estimate for WAVE Life Sciences Ltd. to ($1.09) per share, slightly down from the previous estimate of ($1.07), while maintaining an "Overweight" rating and a $10.00 target price.
• Multiple analysts have issued ratings for WAVE Life Sciences, with a consensus rating of "Moderate Buy" and an average price target of $20.36, amidst expectations of earnings of ($1.14) per share for the current year.
• WAVE Life Sciences recently reported a missing earnings estimate of ($0.31) per share for the last quarter, alongside revenue of $8.70 million, which fell short of the consensus estimate of $11.52 million.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for WAVE Life Sciences in a research note issued on Thursday, July 31st. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings of ($1.09) per share for the year, down from their prior forecast of ($1.07). Cantor Fitzgerald currently has a "Overweight" rating and a $10.00 price target on the stock. The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. Cantor Fitzgerald also issued estimates for WAVE Life Sciences' FY2026 earnings at ($1.29) EPS.

WVE has been the subject of several other reports. Canaccord Genuity Group initiated coverage on WAVE Life Sciences in a research report on Monday. They issued a "buy" rating and a $19.00 price objective for the company. Wall Street Zen downgraded WAVE Life Sciences from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Wells Fargo & Company cut their target price on WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, July 31st. Oppenheimer began coverage on WAVE Life Sciences in a research note on Monday, July 28th. They issued an "outperform" rating and a $24.00 target price on the stock. Finally, Raymond James Financial initiated coverage on shares of WAVE Life Sciences in a report on Wednesday, June 11th. They issued an "outperform" rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $20.27.

WAVE Life Sciences Stock Down 4.2%

Shares of WAVE Life Sciences stock traded down $0.36 on Monday, hitting $8.20. The stock had a trading volume of 604,627 shares, compared to its average volume of 1,302,858. The business's 50 day moving average is $7.38 and its two-hundred day moving average is $8.26. WAVE Life Sciences has a twelve month low of $5.04 and a twelve month high of $16.74. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -9.10 and a beta of -0.95.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). The firm had revenue of $8.70 million during the quarter, compared to the consensus estimate of $11.52 million.

Hedge Funds Weigh In On WAVE Life Sciences

A number of large investors have recently made changes to their positions in WVE. Adage Capital Partners GP L.L.C. boosted its stake in shares of WAVE Life Sciences by 30.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company's stock worth $101,133,000 after purchasing an additional 2,894,396 shares during the period. Price T Rowe Associates Inc. MD boosted its position in WAVE Life Sciences by 63.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock valued at $63,074,000 after buying an additional 1,972,262 shares during the period. Polar Capital Holdings Plc purchased a new stake in WAVE Life Sciences in the 4th quarter valued at about $12,370,000. MPM Bioimpact LLC boosted its position in WAVE Life Sciences by 138.5% in the 4th quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock valued at $18,422,000 after buying an additional 864,766 shares during the period. Finally, Driehaus Capital Management LLC boosted its position in WAVE Life Sciences by 14.6% in the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock valued at $83,033,000 after buying an additional 853,589 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at WAVE Life Sciences

In other news, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $6.95, for a total value of $208,500.00. Following the sale, the director directly owned 282,517 shares in the company, valued at $1,963,493.15. The trade was a 9.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 23.98% of the stock is owned by insiders.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.